April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Safety and Efficacy of Ranibizumab in Asian Patients With Neovascular Age-related Macular Degeneration: 4- and 12-months Results of the EXTEND III Study
Author Affiliations & Notes
  • O. Kwon
    Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  • F. Lee
    Taipei Veterans General Hospital, Taipei, Taiwan
  • H. Chung
    Seoul National University Hospital, Seoul, Republic of Korea
  • C.-C. Lai
    Chang-Gung Memorial Hospital, LinKou, Taiwan
  • S.-J. Sheu
    Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
  • Y.-H. Yoon
    Asan Medical Center, Seoul, Republic of Korea
  • on behalf of the EXTEND III study group
    Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  O. Kwon, None; F. Lee, None; H. Chung, None; C.-C. Lai, None; S.-J. Sheu, None; Y.-H. Yoon, None.
  • Footnotes
    Support  Novartis Pharma
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2365. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. Kwon, F. Lee, H. Chung, C.-C. Lai, S.-J. Sheu, Y.-H. Yoon, on behalf of the EXTEND III study group; Safety and Efficacy of Ranibizumab in Asian Patients With Neovascular Age-related Macular Degeneration: 4- and 12-months Results of the EXTEND III Study. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2365.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of monthly ranibizumab intravitreal injections in Asian patients with neovascular age-related macular degeneration (AMD).

Methods: : In the open-label, single-treatment arm EXTEND III study, 95 AMD patients (12 centers in South Korea and Taiwan) were treated monthly with ranibizumab (0.5 mg) over 12 months. Best-corrected visual acuity (BCVA) was assessed monthly using Early Treatment for Diabetic Retinopathy Study charts. Vascular leakage and lesion size were assessed monthly by fluorescein angiography.

Results: : Adverse events (AEs) were reported in 33.7% of patients. The most frequent ocular AEs were conjunctival hemorrhage (8.4%) and increased intraocular pressure (7.4%). The most frequent non-ocular AEs were nasopharyngitis (4.2%) and prostate cancer (4.2%). Serious AEs occurred in 10.5% of patients with prostate cancer being reported the most frequently (n=4). Ocular SAEs, myocardial infarction, or stroke were not observed. The mean change of BCVA from baseline to Month 4 (primary efficacy endpoint) was 9.3 letters (10.1 letters in Taiwanese and 8.3 letters in Korean patients). At Month 4 65.3% of patients gained ≥5 letters and 27.4% of patients improved by ≥15 letters. 38.9% of patients had complete absence of leakage at Month 4. Mean total lesion area decreased significantly from baseline to Month 4 by 1.79 mm2 to 3.23 mm2. Twelve-month results will be available at the time of presentation.

Conclusions: : The overall safety and efficacy results of this study were consistent with those from earlier pivotal clinical studies performed in Caucasian AMD patients and suggest that monthly treatment with ranibizumab (0.5 mg) on average also improves visual acuity in Asian AMD patients.

Clinical Trial: : www.clinicaltrials.gov NCT00470678

Keywords: age-related macular degeneration • vascular endothelial growth factor • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×